Biogen's 2017 2nd-qtr beats forecasts but leaves investors uncertain

25 July 2017
2019_biotech_test_vial_discovery_big

US biotech Biogen (Nasdaq: BIIB) had an up-and-down morning in the stock market on Tuesday after announcing its results for 2017’s second quarter.

Its share price was 0.3% down after three hours trading as markets digested a set of results that beat analysts’ estimates. The sales total, of $3.1 billion, was 6% higher than the figure for 2016’s second quarter and well above estimates of $2.81 billion, according to the Financial Times.

When excluding all hemophilia revenues from a year ago, the revenue rise is 15%, with Biogen having spun out its business in this therapy area into a quoted company, known as Bioverativ (Nasdaq: BIVV), at the beginning of this year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology